|
||
Independent, up-to-date news and information for the multiple myeloma community. |
|
A recent study published in the journal Medical Oncology determined that the cytokine M-CSF is highly predictive of survival in multiple myeloma patients. In the study, researchers evaluated a diverse set of cytokines to determine their usefulness as prognostic factors in multiple myeloma.
Cytokines are proteins secreted by immune cells to generate an immune response. They are involved with allergic responses, inflammation, blood cell development, and the development of multiple myeloma and other types of cancer.
Currently, the International …
At the recent American Society of Hematology (ASH) annual meeting, there were several presentations comparing a drug regimen of Velcade (bortezomib), thalidomide (Thalomid), and dexamethasone (Decadron), abbreviated as VTD, with a drug regimen of thalidomide and dexamethasone, abbreviated as TD, in newly diagnosed multiple myeloma patients.
Update: VTD Versus TD With Double Autologous Stem Cell Transplantation
One of the ASH presentations showed that the addition of Velcade to a thalidomide-dexamethasone regimen and double autologous stem …
The results from a new study indicate that treatment of newly diagnosed multiple myeloma with novel therapeutic agents improves kidney function in most patients, in comparison to treatment with conventional chemotherapy and a high-dose regimen of dexamethasone (Decadron). The authors of the study presented the results of the clinical trial on December 8 at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition.
Multiple myeloma patients commonly experience complications with kidney function, and kidney impairment is associated …
During this year’s meeting of the American Society of Hematology (ASH), there were several presentations about tanespimycin, a new drug currently being developed by Bristol-Myers Squibb and Kosan Biosciences. Tanespimycin inhibits Hsp90, which acts as a molecular chaperone for proteins critical to the growth, survival, and drug resistance of cancerous cells.
Safety And Activity Profile Of Tanespimycin And Velcade From Phase 1/2 Study
One of the ASH presentations showed that the combination treatment of tanespimycin and Velcade (bortezomib) effectively …
| Brand Name: | |
| Generic Name: | elotuzumab |
| Code Name: | HuLuc63 |
| Company: | Facet Biotech/Bristol-Myers Squibb |
| FDA Clinical Phase: | 1/2 |
Description:
Elotuzumab (news), a monoclonal antibody, selectively targets glycoproteins that are highly expressed on myeloma cells but not on healthy cells. In the presence of elotuzumab, myeloma cells undergo cell lysis and death. Clinical trials are currently underway to examine the activity of elotuzumab …
| Brand Name: | |
| Generic Name: | panobinostat |
| Code Name: | LBH589 |
| Company: | Novartis |
| FDA Clinical Phase: | 1, 2, & 3 |
Description:
Panobinostat (news articles), which is a potent histone deacetylase (HDAC) inhibitor, selectively targets tumor cells for cell death. In Phase 1 trials, panobinostat was highly active as a single agent treatment for several types of cancer, including multiple myeloma, Hodgkin’s lymphoma, acute …
| Brand Name: | Torisel |
| Generic Name: | temsirolimus |
| Code Name: | |
| Company: | Pfizer |
| FDA Clinical Phase: | 1/2 |
Description:
Torisel, which is currently approved for treatment of advanced renal cell carcinoma, is being studied for treatment of multiple myeloma in combination with Velcade (bortezomib) and dexamethasone (Decadron). Torisel …
